c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Ohshima, Yuichiro ^a,b   Yajima, Ichiro ^a   Takeda, Kozue ^a   Iida, Machiko ^a   Kumasaka, Mayuko ^a   Matsumoto, Yoshinari ^b   Kato, Masashi ^a  

^a CHUBU UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; GNDF RECEPTOR ALPHA 1; PROTEIN RET; UNCLASSIFIED DRUG; GDNF PROTEIN, HUMAN; GDNF PROTEIN, MOUSE; GFRA1 PROTEIN, HUMAN; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; MELANOMA; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOGENE RET; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR VOLUME; UPREGULATION; ANIMAL; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; TUMOR CELL LINE;

MURINAE; MUS; MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HUMANS; MELANOMA; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-RET; RNA, MESSENGER;

EID: 77955350230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010279     Document Type: Article

References (27)

1. Hussein MR (2005) Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol 58: 453-456.
2. Takahashi M (2001) The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12: 361-373.
3. Trupp M, Scott R, Whittemore SR, Ibanez CF (1999) Ret-dependent and - independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 274: 20885-20894.
4. Kato M, Iwashita T, Takeda K, Akhand AA, Liu W, et al. (2000) Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases. Mol Biol Cell 11: 93-101.
5. Jijiwa M, Fukuda T, Kawai K, Nakamura A, Kurokawa K, et al. (2004) A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol Cell Biol 24: 8026-8036.
6. Drosten M, Putzer BM (2006) Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 3: 564-574.
7. Kato M, Takeda K, Kawamoto Y, Iwashita T, Akhand AA, et al. (2002) Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of thyrosines in the COOH-terminal kinase domain for phenylalanine. Cancer Res 62: 2414-2422.
8. Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, et al. (1999) Cosegregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? Hum Mutat 13: 331-336.
9. Kato M, Iwashita T, Akhand AA, Liu W, Takeda K, et al. (2000) Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation. Antioxid Redox Signal. Winter 2: 841-849.
10. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, et al. (1998) Transgenic mouse model for skin malignant melanoma. Oncogene 17: 1885-1888.
11. Kato M, Takeda K, Kawamoto Y, Tsuzuki T, Hossain K, et al. (2004) c-Kittargeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res 64: 801-806.
12. Easty DJ, Herlyn M, Bennett DC (1995) Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer 60: 129-136.
13. Narita N, Tanemura A, Murali R, Scolyer RA, Huang S, et al. (2009) Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 28: 3058-68.
14. Oka M, Ogita K, Ando H, Horikawa T, Hayashibe K, et al. (1996) Deletion of specific protein kinase C subspecies in human melanoma cells. J Cell physiol 167: 406-412.
15. Emionite L, Galmozzi F, Raffo P, Vergani L, Toma S (2003) Retinoids and malignant melanoma: a pathway of proliferation inhibition on SK MEL28 cell line. Anticancer Res 23: 13-19.
16. Yajima I, Kumasaka M, Thang ND, Yanagishita T, Ohgami N, et al. (2009) Zinc finger protein 28 as a novel melanoma-related molecule. J Dermatol Sci 55: 68-70.
17. Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, et al. (2006) Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 37: 199-212.
18. Kato M, Ohgami N, Kawamoto Y, Tsuzuki T, Hossain K, et al. (2007) Protective effect of hyperpigmented skin on UV-mediated cutaneous cancer development. J Invest Dermatol 127: 1244-9.
19. Peterson S, Bogenmann E (2004) The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene 23: 213-25.
20. Zeng Q, Cheng Y, Zhu Q, Yu Z, Wu X, et al. (2008) The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res 36: 656-664.
21. Iwahashi N, Nagasaka T, Tezel G, Iwashita T, Asai N, et al. (2002) Expression of glial cell line-derived neurotrophic factor correlates with perineural invasion of bile duct carcinoma. Cancer 94: 167-174.
22. Garnis C, Davies JJ, Buys TP, Tsao MS, MacAulay C, et al. (2005) Chromosome 5p aberrations are events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene 24: 4806-4812.
23. Esseghir S, Todd SK, Hunt T, Poulsom R, Plaza-Menacho I, et al. (2007) A role for glial cell line-derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res 67: 11732-11741.
24. Kumasaka YM, Yajima I, Hossain K, Iida M, Tsuzuki T, et al. (2010) A Novel Mouse Model for de novo melanoma. Cancer Res (in press).
25. Kato M, Wickner W (2003) Vam 10p defines a Sec 18p-independent step of priming that allows yeast vacuole tethering. Proc Natl Acad Sci USA 100: 6398-6403.
26. Kato M, Pu MY, Isobe K, Iwamoto T, Nagase F, et al. (1994) Characterization of the immunoregulatory action of saikosaponin-d. Cell Immunol 159: 15-25.
27. Hasselblatt M, Mertsch S, Koos B, Riesmeier B, Stegemann H, et al. (2009) TWIST-1 is overexpressed in neoplastic choroid plexus epithelial cells and promotes proliferation and invasion. Cancer Res 69: 2219-2223.